PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
89.55
+0.98 (1.11%)
At close: Jul 9, 2026, 4:00 PM EDT
89.99
+0.44 (0.49%)
Pre-market: Jul 10, 2026, 5:08 AM EDT
PTC Therapeutics Revenue
PTC Therapeutics had revenue of $272.55M in the quarter ending March 31, 2026, a decrease of -76.83%. This brings the company's revenue in the last twelve months to $827.11M, down -53.34% year-over-year. In the year 2025, PTC Therapeutics had annual revenue of $1.73B with 114.51% growth.
Revenue (ttm)
$827.11M
Revenue Growth
-53.34%
P/S Ratio
8.98
Revenue / Employee
$834,622
Employees
991
Market Cap
7.43B
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.73B | 923.88M | 114.51% |
| Dec 31, 2024 | 806.78M | -131.04M | -13.97% |
| Dec 31, 2023 | 937.82M | 239.02M | 34.20% |
| Dec 31, 2022 | 698.80M | 160.21M | 29.75% |
| Dec 31, 2021 | 538.59M | 157.83M | 41.45% |
| Dec 31, 2020 | 380.77M | 73.79M | 24.04% |
| Dec 31, 2019 | 306.98M | 42.25M | 15.96% |
| Dec 31, 2018 | 264.73M | 70.34M | 36.19% |
| Dec 31, 2017 | 194.39M | 111.69M | 135.04% |
| Dec 31, 2016 | 82.71M | 45.94M | 124.95% |
| Dec 31, 2015 | 36.77M | 11.52M | 45.64% |
| Dec 31, 2014 | 25.25M | -9.45M | -27.24% |
| Dec 31, 2013 | 34.70M | 750.00K | 2.21% |
| Dec 31, 2012 | 33.95M | -71.47M | -67.80% |
| Dec 31, 2011 | 105.41M | 100.45M | 2,022.34% |
| Dec 31, 2005 | 4.97M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| TG Therapeutics | 700.35M |
| Mirum Pharmaceuticals | 569.61M |
| Ligand Pharmaceuticals | 274.48M |
| Rhythm Pharmaceuticals | 217.17M |
| Xenon Pharmaceuticals | 7.50M |
PTCT News
- 2 days ago - PTC Therapeutics price target raised to $85 from $82 at RBC Capital - TheFly
- 22 days ago - PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 24 days ago - PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes - PRNewsWire
- 24 days ago - PTC Therapeutics files to sell $500M of Convertible Senior Notes due 2031 - TheFly
- 24 days ago - PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes - PRNewsWire
- 4 weeks ago - PTC Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 4 weeks ago - PTC Therapeutics assumed with Buy from Neutral at Citi - TheFly
- 5 weeks ago - PTC Therapeutics Transcript: AGM 2026 - Transcripts